WO1991011462A3 - Fragments de merosine codant des acides nucleiques, et leurs emplois - Google Patents

Fragments de merosine codant des acides nucleiques, et leurs emplois Download PDF

Info

Publication number
WO1991011462A3
WO1991011462A3 PCT/US1991/000631 US9100631W WO9111462A3 WO 1991011462 A3 WO1991011462 A3 WO 1991011462A3 US 9100631 W US9100631 W US 9100631W WO 9111462 A3 WO9111462 A3 WO 9111462A3
Authority
WO
WIPO (PCT)
Prior art keywords
merosin
fragments
nucleic acids
acids encoding
laminin
Prior art date
Application number
PCT/US1991/000631
Other languages
English (en)
Other versions
WO1991011462A2 (fr
Inventor
Eva Engvall
Ilmo Leivo
Joshua R Sanes
Original Assignee
Jolla Cancer Res Found
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found, Univ Washington filed Critical Jolla Cancer Res Found
Priority to DE69132159T priority Critical patent/DE69132159T2/de
Priority to AT91904841T priority patent/ATE192458T1/de
Priority to JP91505550A priority patent/JPH05506435A/ja
Priority to EP91904841A priority patent/EP0514481B1/fr
Priority to KR1019920700723A priority patent/KR920702437A/ko
Publication of WO1991011462A2 publication Critical patent/WO1991011462A2/fr
Publication of WO1991011462A3 publication Critical patent/WO1991011462A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Protéine purifiée présentant une masse moléculaire apparante d'environ 800 kDa, appelée mérosine. L'invention concerne également une variante de laminine hétérotrimère sensiblement pure, comprenant la structure M-X-B2, dans laquelle M représente le polypeptide M de mérosine; X est sélectionné dans le groupe composé de la chaîne B1 de laminine et de S-laminine; et B2 représente la chaîne B2 de laminine. L'invention concerne également une séquence d'acides nucléiques isolée, codant la mérosine. En outre, l'invention concerne des anticorps, des vecteurs, ainsi que l'expression de protéines recombinées à l'aide d'un système de vecteurs hôtes. On décrit également l'utilisation de mérosine afin de stimuler la croissance de neurites.
PCT/US1991/000631 1990-01-30 1991-01-30 Fragments de merosine codant des acides nucleiques, et leurs emplois WO1991011462A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69132159T DE69132159T2 (de) 1990-01-30 1991-01-30 Merosin, dafür kodierende nukleinsäuren, fragmente und deren verwendung
AT91904841T ATE192458T1 (de) 1990-01-30 1991-01-30 Merosin, dafür kodierende nukleinsäuren, fragmente und deren verwendung
JP91505550A JPH05506435A (ja) 1990-01-30 1991-01-30 メロシン、それをコードする核酸、フラグメントおよびその使用
EP91904841A EP0514481B1 (fr) 1990-01-30 1991-01-30 Fragments de merosine codant des acides nucleiques, et leurs emplois
KR1019920700723A KR920702437A (ko) 1990-08-01 1991-07-31 성형 물품의 적어도 표면부가 스티렌 중합체 또는 공중합체로 이루어져 있어서, 그 표면 외관을 수정시키지 않고도 상기 물품에 영속적인 정전기 방지 특성을 주는, 정전기 방지성 투명 박막을 성형 물품의 표면에 피복시키는 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47231990A 1990-01-30 1990-01-30
US472,319 1990-01-30
US58768990A 1990-09-24 1990-09-24
US587,689 1990-09-24

Publications (2)

Publication Number Publication Date
WO1991011462A2 WO1991011462A2 (fr) 1991-08-08
WO1991011462A3 true WO1991011462A3 (fr) 1991-10-03

Family

ID=27043723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/000631 WO1991011462A2 (fr) 1990-01-30 1991-01-30 Fragments de merosine codant des acides nucleiques, et leurs emplois

Country Status (8)

Country Link
US (1) US5444158A (fr)
EP (1) EP0514481B1 (fr)
JP (1) JPH05506435A (fr)
AT (1) ATE192458T1 (fr)
AU (1) AU7334291A (fr)
CA (1) CA2074361A1 (fr)
DE (1) DE69132159T2 (fr)
WO (1) WO1991011462A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872231A (en) * 1990-01-30 1999-02-16 La Jolla Cancer Research Foundation Nucleic acids encoding merosin
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5770562A (en) * 1991-03-26 1998-06-23 Oregon Health Sciences University Products and methods for improving keratinocyte adhesion to the dermis
US5863743A (en) * 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
AU4678400A (en) 1999-04-30 2000-11-17 Biostratum, Inc. Laminin 8 and methods for its use
JP2002542823A (ja) 1999-04-30 2002-12-17 ユニヴァースティ オブ メディシン アンド デンティストリー オブ ニュージャージー ロバート ウッド ジョンソン メディカル スクール ラミニン２とその使用方法
US6703363B1 (en) * 1999-04-30 2004-03-09 Biostratum, Inc. Recombinant laminin 5
SI2211851T1 (sl) * 2007-10-09 2014-11-28 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Laminin-1 za uporabo pri izboljĺ anju regeneracije miĺ ice po poĺ kodbi ali za izboljĺ anje celjenja ran ob sistemski administraciji
KR101219512B1 (ko) * 2011-03-15 2013-01-11 서울대학교산학협력단 세포 부착, 퍼짐, 이동 및 신경돌기 성장을 촉진하는 인간 라미닌 α２ 사슬의 ＬＧ３ 도메인 및 활성 펩티드
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
CA2919952A1 (fr) 2013-03-15 2014-09-18 Dean Burkin Methodes de traitement de la dystrophie musculaire

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 112, no. 3, 1983, pages 1091 - 1098 *
CELL REGULATION, vol. 1, no. 10, 1991, pages 731 - 740 *
DATABASE CAPLUS [online] 20 June 1983 (1983-06-20), "ISOLATION OF LAMININ FROM HUMAN PLACENTAL BASEMENT MEMBRANES: AMNION, CHORION AND CHORIONIC MICROVESSELS", XP002084299, accession no. STN Database accession no. 1983:213310 *
DATABASE CAPLUS [online] 4 March 1991 (1991-03-04), "DISTRIBUTION AND ISOLATION OF FOUR LAMININ VARIANTS:TISSUES RESTRICTED DISTRIBUTION OF HETREOTRIMERS ASSEMBLED FROM FIVE DIFFERENT SUBUNITS", XP002084300, accession no. STN Database accession no. 1991:79032 *
XP002084296 *
XP002084297 *
XP002084298 *

Also Published As

Publication number Publication date
EP0514481B1 (fr) 2000-05-03
DE69132159T2 (de) 2001-01-11
DE69132159D1 (de) 2000-06-08
AU7334291A (en) 1991-08-21
US5444158A (en) 1995-08-22
WO1991011462A2 (fr) 1991-08-08
EP0514481A1 (fr) 1992-11-25
JPH05506435A (ja) 1993-09-22
ATE192458T1 (de) 2000-05-15
CA2074361A1 (fr) 1991-07-31

Similar Documents

Publication Publication Date Title
ATE99656T1 (de) Ferritinanaloge.
WO1997004097A3 (fr) Proteines humaines ctla-8 et utilisation de proteines apparentees aux proteines ctla-8
AU7508794A (en) Novel lipase, microorganism producing the lipase, process for producing the lipase, and use of the lipase
CA2267670A1 (fr) Methode pour preparer des cellules humaines a facteur souches polypeptide
AU5428486A (en) Phenyl carbamates
EP0833912A4 (fr) Nouvelle cytokine de type facteur de croissance transformant tgf-beta
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
AU7334291A (en) Merosin, nucleic acids encoding, fragments and uses thereof
CA2173626A1 (fr) Chaine b1k de laminine et procedes d'utilisation
WO1999015666A3 (fr) Chemokine derivee de macrophages (mdc), analogues de mdc, substances inhibitrices de mdc et utilisations correspondants
CA2240296A1 (fr) Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
AU2978697A (en) Novel peptide, process for the production of the same, and use of the same
DE69228749T2 (de) Neuartige polypeptide und ihre verwendung
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
AU6963491A (en) Antihemostatic factor vii peptides
EP0362520A3 (fr) Antibiotique, mersacidine, procédé pour l'obtenir et son utilisation comme médicament
AU5192790A (en) Human elastase inhibitor
AU3893493A (en) Micro-organisms, preparation method therefor and uses thereof
AU4483696A (en) Novel peptides, their production and use
MX9605402A (es) Nueva sustancia activa peptidica y su obtencion.
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
CA2261041A1 (fr) Souches du bacillus thuringiensis presentant une production accrue de certaines proteines en cristaux toxiques pour les lepidopteres
IL91137A0 (en) Process for the enantiospecific synthesis of intermediates for hexahydro-benzo(d)-naphtho(2,1-b)azepines
AU1305097A (en) Protein induced by deprenyl$m(3)
AU5239290A (en) Purification of c.pseudotuberculosis toxin, and cloning and expression of toxin gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2074361

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991904841

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1991904841

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991904841

Country of ref document: EP